Rüdiger Nave

Summary

Publications

  1. ncbi Pharmacokinetics of teduglutide in subjects with renal impairment
    Rüdiger Nave
    Nycomed GmbH, Nycomed a Takeda company, Constance, Germany
    Eur J Clin Pharmacol 69:1149-55. 2013
  2. ncbi Single-dose and multi-dose delivery systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study
    Rüdiger Nave
    Nycomed, A Takeda Company, Konstanz, Germany
    Int J Clin Pharmacol Ther 50:751-9. 2012
  3. ncbi Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain
    Nele Kaessner
    Nycomed a Takeda company, Konstanz, Germany
    Int J Clin Pharmacol Ther 50:665-77. 2012

Detail Information

Publications3

  1. ncbi Pharmacokinetics of teduglutide in subjects with renal impairment
    Rüdiger Nave
    Nycomed GmbH, Nycomed a Takeda company, Constance, Germany
    Eur J Clin Pharmacol 69:1149-55. 2013
    ..This study was designed to study the influence of renal function and age on teduglutide pharmacokinetics...
  2. ncbi Single-dose and multi-dose delivery systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study
    Rüdiger Nave
    Nycomed, A Takeda Company, Konstanz, Germany
    Int J Clin Pharmacol Ther 50:751-9. 2012
    ..The aim of this study was to demonstrate the pharmacokinetic bioequivalence of INFS single dose delivery system (SDS) in relation to the currently marketed MDS device...
  3. ncbi Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain
    Nele Kaessner
    Nycomed a Takeda company, Konstanz, Germany
    Int J Clin Pharmacol Ther 50:665-77. 2012
    ..The pharmacokinetics (PK) of INFS was well characterized in healthy subjects, while PK investigations in cancer patients are limited...